JP2012502014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502014A5 JP2012502014A5 JP2011525613A JP2011525613A JP2012502014A5 JP 2012502014 A5 JP2012502014 A5 JP 2012502014A5 JP 2011525613 A JP2011525613 A JP 2011525613A JP 2011525613 A JP2011525613 A JP 2011525613A JP 2012502014 A5 JP2012502014 A5 JP 2012502014A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- optionally substituted
- following formula
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 102000011727 Caspases Human genes 0.000 claims 3
- 108010076667 Caspases Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 150000003852 triazoles Chemical class 0.000 claims 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 125000005331 diazinyl group Chemical class N1=NC(=CC=C1)* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003527 tetrahydropyrans Chemical class 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0816294.3 | 2008-09-05 | ||
| GB0816294A GB0816294D0 (en) | 2008-09-05 | 2008-09-05 | Compounds |
| GB0818076.2 | 2008-10-02 | ||
| GB0818076A GB0818076D0 (en) | 2008-10-02 | 2008-10-02 | Compounds |
| PCT/GB2009/002132 WO2010026388A1 (en) | 2008-09-05 | 2009-09-04 | Isatin derivatives for use as in vivo imaging agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502014A JP2012502014A (ja) | 2012-01-26 |
| JP2012502014A5 true JP2012502014A5 (enExample) | 2012-10-25 |
| JP5667056B2 JP5667056B2 (ja) | 2015-02-12 |
Family
ID=41181051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525613A Expired - Fee Related JP5667056B2 (ja) | 2008-09-05 | 2009-09-04 | インビボ画像化剤として使用されるイサチン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8961930B2 (enExample) |
| EP (1) | EP2367816B1 (enExample) |
| JP (1) | JP5667056B2 (enExample) |
| KR (1) | KR20110066927A (enExample) |
| CN (1) | CN102171208A (enExample) |
| AU (1) | AU2009289062B2 (enExample) |
| CA (1) | CA2735970A1 (enExample) |
| MX (1) | MX2011002498A (enExample) |
| RU (1) | RU2535975C2 (enExample) |
| WO (1) | WO2010026388A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2828810A1 (en) | 2011-03-01 | 2012-09-07 | Ge Healthcare Limited | Radiolabelled octreotate analogues as pet tracers |
| GB201121911D0 (en) | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Radiofluorination method |
| CN103183631B (zh) * | 2011-12-28 | 2016-08-24 | 天津市国际生物医药联合研究院 | 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用 |
| EP3456718B1 (en) * | 2016-05-10 | 2021-02-17 | Fundaçâo Oswaldo Cruz | Isatin-derived compounds, use of the compounds for the treatment of aids and hbv infections |
| CN115171929B (zh) * | 2021-04-01 | 2024-07-16 | 中核核电运行管理有限公司 | 重水堆机组给水支管与燃料通道小间隙问题处理的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1240648A (en) | 1967-08-16 | 1971-07-28 | Wyeth John & Brother Ltd | N-substituted isatins |
| AR016384A1 (es) | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
| AU7625500A (en) | 1999-09-30 | 2001-04-30 | Smithkline Beecham Corporation | Caspases and apoptosis |
| PT1255752E (pt) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
| RU2259999C2 (ru) * | 2003-08-26 | 2005-09-10 | ООО "Исследовательский институт химического разнообразия" | 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения |
| GB0327494D0 (en) | 2003-11-26 | 2003-12-31 | Amersham Plc | Novel imaging agents |
| US7270799B2 (en) | 2004-01-15 | 2007-09-18 | Nst Neurosurvival Technologies Ltd. | Perturbed membrane-binding compounds and methods of using the same |
| US7256198B2 (en) * | 2004-02-18 | 2007-08-14 | Wyeth | Pyrimidoindolones and methods for using same |
| GB0428012D0 (en) | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
| AU2005324905B2 (en) * | 2005-01-17 | 2012-01-19 | Universitaetsklinikum Muenster | 5-pyrrolidinylsulfonyl isatin derivatives |
-
2009
- 2009-09-04 US US13/062,064 patent/US8961930B2/en active Active
- 2009-09-04 WO PCT/GB2009/002132 patent/WO2010026388A1/en not_active Ceased
- 2009-09-04 EP EP09785058.0A patent/EP2367816B1/en not_active Not-in-force
- 2009-09-04 JP JP2011525613A patent/JP5667056B2/ja not_active Expired - Fee Related
- 2009-09-04 MX MX2011002498A patent/MX2011002498A/es not_active Application Discontinuation
- 2009-09-04 AU AU2009289062A patent/AU2009289062B2/en not_active Ceased
- 2009-09-04 CA CA2735970A patent/CA2735970A1/en not_active Abandoned
- 2009-09-04 RU RU2011112075/04A patent/RU2535975C2/ru not_active IP Right Cessation
- 2009-09-04 KR KR1020117007647A patent/KR20110066927A/ko not_active Ceased
- 2009-09-04 CN CN2009801389781A patent/CN102171208A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buchmann et al. | [18F] 3'-Deoxy-3'-Fluorothymidine-PET in NHL Patients: Whole-Body Biodistribution and Imaging of Lymphoma Manifestations—a Pilot Study | |
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2012502014A5 (enExample) | ||
| Dummer et al. | Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma | |
| Pieper et al. | Speckle-tracking 2-dimensional strain echocardiography: a new noninvasive imaging tool to evaluate acute rejection in cardiac transplantation | |
| Thibault et al. | Acute myocardial infarction in mice: assessment of transmurality by strain rate imaging | |
| JP2019527225A5 (enExample) | ||
| Bauman et al. | [18F]-DCFPyL positron emission tomography/magnetic resonance imaging for localization of dominant intraprostatic foci: first experience | |
| JP2007515467A5 (enExample) | ||
| JP2009538894A5 (enExample) | ||
| Abele et al. | Lymphoscintigraphy in early-stage non-small cell lung cancer with technetium-99m nanocolloids and hybrid SPECT/CT: a pilot project | |
| JP2023184564A (ja) | 新規化合物 | |
| JP2013509378A5 (enExample) | ||
| RU2011112075A (ru) | Производные изатина для применения в качестве агентов визуализации in vivo | |
| JP2013507345A5 (enExample) | ||
| GW Kosterink | Positron emission tomography in the diagnosis and treatment management of tuberculosis | |
| JP2012520855A5 (enExample) | ||
| WO2022026533A1 (en) | Methods and materials for using [18f]-f-arag in cardiac imaging | |
| US20240190858A1 (en) | Crystalline forms, pharmaceutical compositions and methods of use thereof | |
| KR20160086962A (ko) | 삼중 음성 유방 암 치료를 위해 카보플라틴과 병용된 벨리파리브 | |
| Schelbert et al. | PET imaging in small animals | |
| Hou et al. | Noninvasive monitoring and evaluation of the renal structure and function in a mouse model of unilateral ureteral occlusion using microcomputed tomography | |
| Miller et al. | Variation of diagnostic ultrasound-induced pulmonary capillary hemorrhage with fraction of inspired oxygen | |
| JP7054134B2 (ja) | ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング | |
| Reiter et al. | Intrathoracic Desmoid Type Fibromatosis: A Case Report and Literature Review. |